Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tilray medicinal cannabis
- Development stage
- Phase 3
- Lead developer
- Tilray
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Tilray medicinal cannabis refers to GMP-certified botanical cannabis products developed by Tilray Brands (formerly Tilray Canada). In the context of a specific safety assessment study conducted in partnership with the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, these products were evaluated for their impact on driving performance. The study utilized two specific formulations: a high-THC variety and a balanced 1:1 THC:CBD variety, both administered via vaporization. The active components, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), interact with the endocannabinoid system, specifically targeting CB1 and CB2 receptors in the central nervous system. While THC is known for its psychoactive effects and potential for impairment, CBD is non-intoxicating. The driving study concluded that THC-dominant cannabis caused temporary impairment, whereas CBD-dominant cannabis did not significantly affect driving ability.
- Brand names
- Tilray
- Other names
- Medicinal cannabisCannabinoidsTHC:CBD 1:1High THC cannabis
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Tilray medicinal cannabis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tilray medicinal cannabis.